Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Kiniksa Pharmaceuticals International, plc changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 92 | 1 | 104 | +13 |
| Shares | 29.9M | 9.50K | 29.9M | +2.05K (0.0%) |
| Value | $290.5M | $92.0K | $383.2M | +$92.8M (+31.9%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (9)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Great Point Partners LLC | 1,204,028 | $11.7M |
| Opaleye Management Inc. | 814,250 | $7.89M |
| Woodline Partners LP | 332,893 | $3.23M |
| Integral Health Asset Management, LLC | 234,830 | $2.28M |
| Engineers Gate Manager LP | 14,482 | $140.0K |
| Lazard Asset Management LLC | 10,546 | $102.0K |
| Group One Trading, L.P. | 1,276 | $12.0K |
| Caption Management, LLC | 1,184 | $11.0K |
| National Bank of Canada | 500 | $5.00K |
Not filed for Q3 2022 yet (1)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exane Derivatives | 9,496 | $92.0K |